Vera Papochieva

Vera Papochieva


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Antibodies
Verified
Journal Article
Open access
PDF file
Polina Yordanova KostovaPolina Yordanova Kostova
Polina Yordanova Kostova
VPVera Papochieva
Vera Papochieva
DMDimitrinka Miteva
Dimitrinka Miteva
BGBilyana Georgieva
Bilyana Georgieva
SMSirma Mileva
Sirma Mileva
GPGuergana Petrova
Guergana Petrova
Elevated immunoglobulin E (IgE) is a hallmark of allergic diseases. However, high IgE levels also occur in a number of other infectious and noninfectious diseases. In most cases, elevated IgE levels indicate allergy, eczema, or chronic skin infection. Very high IgE levels are not uncommon in patients with active eczema but more often indicate monogenic atopic disorder or inborn errors of immunity with an atopic phenotype. We conducted a retrospective study of 385 children with suspected immune deficiency referred to the clinic over a 9-year period. Measurement of IgE, IgG, IgA, IgM, and IgG subclasses in blood samples revealed that nearly one-third of the patients had elevated serum IgE levels. Most of the cases with elevated IgE were children with underlying atopy—mainly atopic dermatitis and, to a lesser extent, bronchial asthma—whereas 40.12% (37 children) had no atopy at all. In the most severe cases (with extremely elevated IgE or severe dermatitis), we confirmed genetic mutations for underlying immunodeficiency. Our results indicate that allergic phenotype should not be underestimated and that children with more severe allergic disease should be evaluated for an underlying inborn error of immunity. If inborn error of immunity (IEI) is suspected, a comprehensive immunologic evaluation is required. Genetic testing helps identify the specific genetic abnormality, which provides important insight into the immunopathogenesis of the disease and accurate determination of optimal therapy.

20 March 2014 in Cough
Verified
Journal Article
Open access
PDF file
RMRoxana K Mincheva
Roxana K Mincheva
TKTanya Z Kralimarkova
Tanya Z Kralimarkova
MRMiroslava Rasheva
Miroslava Rasheva
ZDZlatko Dimitrov
Zlatko Dimitrov
DNDenislava Nedeva
Denislava Nedeva
TPTodor Popov
Todor Popov
Different conditions make the proximal airways susceptible to tussigenic stimuli in the chronic cough (CC) syndrome. Leukotrienes can be implicated in the inflammatory mechanism at play in it. Montelukast is a selective cysteinyl-leukotriene receptor antagonist with proven effectiveness in patients with asthma. The aim of our real-life pilot study was to use montelukast to relieve cough symptoms in patients with CC allegedly due to the two frequent causes other than asthma – upper airway cough syndrome and gastroesophageal reflux (GER).

1 September 2016 in Journal of Biomedical and Clinical Research
Verified
Journal Article
Open access
PDF file
VPVera Papochieva
Vera Papochieva
DMDimitrinka S. Miteva
Dimitrinka S. Miteva
PPPenka I. Perenovska
Penka I. Perenovska
GPGuergana Petrova
Guergana Petrova